Stocks News

LAST PRICE
223.2900
TODAY'S CHANGE (%)
Trending Down-6.2900 (-2.7398%)

Bid / Lots
222.0000/ 1
Ask / Lots
245.0000/ 8
Open / Previous Close
233.5500 / 229.5800
Day Range
Low 222.7200
High 233.5500
52 Week Range
Low 119.7604
High 299.9800
Volume
808,162
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

May 17, 2024
- Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing, from 3:08AM ET on Friday May 17, 2024 by MT Newswires
  3:08AM ET on Friday May 17, 2024 by MT Newswires
  Companies Mentioned: MDGL
  03:08 AM EDT, 05/17/2024 (MT Newswires) -- Fred B Craves, Director, on May 14, 2024, sold 22,489 shares in Madrigal Pharmaceuticals (MDGL) for $4,787,404. Following the Form 4 filing with the SEC, Craves has control over a total of 489,685 shares of...
May 10, 2024
- DJ Madrigal Pharmaceuticals Is Maintained at Neutral by B. Riley Securities, from 8:55AM ET on Friday May 10, 2024 by Dow Jones
  8:55AM ET on Friday May 10, 2024 by Dow Jones
  Companies Mentioned: MDGL
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 10, 2024 08:55 ET (12:55 GMT)
- B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating, from 8:51AM ET on Friday May 10, 2024 by MT Newswires
  8:51AM ET on Friday May 10, 2024 by MT Newswires
  Companies Mentioned: MDGL
  08:51 AM EDT, 05/10/2024 (MT Newswires) -- Madrigal Pharmaceuticals (MDGL) has an average rating of outperform and price targets ranging from $155 to $372, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and econom...
May 9, 2024
- UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating, from 10:53AM ET on Thursday May 09, 2024 by MT Newswires
  10:53AM ET on Thursday May 09, 2024 by MT Newswires
  Companies Mentioned: MDGL
  10:53 AM EDT, 05/09/2024 (MT Newswires) -- Madrigal Pharmaceuticals (MDGL) has an average outperform rating and price target range of $150 to $507, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic resea...
May 8, 2024
- DJ Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 3:42PM ET on Wednesday May 08, 2024 by Dow Jones
  3:42PM ET on Wednesday May 08, 2024 by Dow Jones
  Companies Mentioned: MDGL
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/MDGL/analyst-ratings
  
  (END) Dow Jones Newswires
  
  May 08, 2024 15:42 ET (19:42 GMT)

Today
- UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating, from 7 hours ago by MT Newswires
  7 hours ago by MT Newswires
  Companies Mentioned: BBIO
May 24, 2024
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting, from 7:30AM ET on Friday May 24, 2024 by GlobeNewswire
  7:30AM ET on Friday May 24, 2024 by GlobeNewswire
  Companies Mentioned: BBIO
May 23, 2024
- Krystal Biotech Insider Sold Shares Worth $3,282,690, According to a Recent SEC Filing, from 3:49AM ET on Thursday May 23, 2024 by MT Newswires
  3:49AM ET on Thursday May 23, 2024 by MT Newswires
  Companies Mentioned: KRYS
May 17, 2024
- Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing, from 4:48PM ET on Friday May 17, 2024 by MT Newswires
  4:48PM ET on Friday May 17, 2024 by MT Newswires
  Companies Mentioned: NUVL
- Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast, from 9:00AM ET on Friday May 17, 2024 by Business Wire
  9:00AM ET on Friday May 17, 2024 by Business Wire
  Companies Mentioned: IBRX
May 16, 2024
- Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate, from 4:23PM ET on Thursday May 16, 2024 by MT Newswires
  4:23PM ET on Thursday May 16, 2024 by MT Newswires
  Companies Mentioned: NUVL
- Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655, from 4:01PM ET on Thursday May 16, 2024 by PR Newswire
  4:01PM ET on Thursday May 16, 2024 by PR Newswire
  Companies Mentioned: NUVL
- Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm, from 10:34AM ET on Thursday May 16, 2024 by Newsfile
  10:34AM ET on Thursday May 16, 2024 by Newsfile
  Companies Mentioned: IBRX
May 15, 2024
- Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information, from 1:56PM ET on Wednesday May 15, 2024 by GlobeNewswire
  1:56PM ET on Wednesday May 15, 2024 by GlobeNewswire
  Companies Mentioned: BTAI, BAX, EGRX, IBRX
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4), from 7:30AM ET on Wednesday May 15, 2024 by GlobeNewswire
  7:30AM ET on Wednesday May 15, 2024 by GlobeNewswire
  Companies Mentioned: BBIO

Madrigal Pharmaceuticals Inc
NASDAQ:MDGLUnited States

Search Criteria

May 17, 2024

Madrigal Pharmaceuticals Insider Sold Shares Worth $4,787,404, According to a Recent SEC Filing, from 3:08AM ET on Friday May 17, 2024 by MT Newswires

May 10, 2024

DJ Madrigal Pharmaceuticals Is Maintained at Neutral by B. Riley Securities, from 8:55AM ET on Friday May 10, 2024 by Dow Jones

B. Riley Cuts Madrigal Pharmaceuticals' Price Target to $200 From $270, Keeps Neutral Rating, from 8:51AM ET on Friday May 10, 2024 by MT Newswires

May 9, 2024

UBS Adjusts Price Target on Madrigal Pharmaceuticals to $411 From $410, Maintains Buy Rating, from 10:53AM ET on Thursday May 09, 2024 by MT Newswires

May 8, 2024

DJ Madrigal Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co., from 3:42PM ET on Wednesday May 08, 2024 by Dow Jones

Peers Headlines

Today

UBS Adjusts Price Target on BridgeBio Pharma to $47 From $51, Maintains Buy Rating, from 7 hours ago by MT Newswires

May 24, 2024

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting, from 7:30AM ET on Friday May 24, 2024 by GlobeNewswire

May 23, 2024

Krystal Biotech Insider Sold Shares Worth $3,282,690, According to a Recent SEC Filing, from 3:49AM ET on Thursday May 23, 2024 by MT Newswires

May 17, 2024

Nuvalent Insider Sold Shares Worth $345,450, According to a Recent SEC Filing, from 4:48PM ET on Friday May 17, 2024 by MT Newswires

Connecting the Dots of ANKTIVA's Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday Podcast, from 9:00AM ET on Friday May 17, 2024 by Business Wire

May 16, 2024

Nuvalent Gets Breakthrough Therapy Designation for Lung Cancer Treatment Candidate, from 4:23PM ET on Thursday May 16, 2024 by MT Newswires

Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-655, from 4:01PM ET on Thursday May 16, 2024 by PR Newswire

Kuehn Law Encourages Investors of ImmunityBio, Inc. to Contact Law Firm, from 10:34AM ET on Thursday May 16, 2024 by Newsfile

May 15, 2024

Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information, from 1:56PM ET on Wednesday May 15, 2024 by GlobeNewswire

BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4), from 7:30AM ET on Wednesday May 15, 2024 by GlobeNewswire